These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
3. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure. Weber KT; Janicki JS; Jain MC J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397 [TBL] [Abstract][Full Text] [Related]
4. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Uretsky BF; Valdes AM; Reddy PS Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328 [TBL] [Abstract][Full Text] [Related]
5. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. Colucci WS; Wright RF; Braunwald E N Engl J Med; 1986 Feb; 314(6):349-58. PubMed ID: 2418353 [No Abstract] [Full Text] [Related]
6. Treatment of heart failure with enoximone, a new phosphodiesterase inhibitor. Düsseldorf, Federal Republic of Germany. September 25-27, 1987. Proceedings. J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S1-S83. PubMed ID: 2480479 [No Abstract] [Full Text] [Related]
7. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone]. Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895 [TBL] [Abstract][Full Text] [Related]
8. [Effect of oral long-term enoximone therapy on the arrhythmia profile in chronic heart failure]. Treese N; Rhein S; Werneyer A; Erbel R; von Olshausen K; Pop T; Meyer J Z Kardiol; 1988 Oct; 77(10):653-9. PubMed ID: 2467449 [TBL] [Abstract][Full Text] [Related]
9. Enoximone as a bridge to heart transplantation: the Utah experience. O'Connell JB; Gilbert EM; Renlund DG; Bristow MR J Heart Lung Transplant; 1991; 10(3):477-81. PubMed ID: 1830222 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation]. Gibelin P; Garraffo R; Sbirrazzuoli V; Lapalus P; Morand P Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():75-81. PubMed ID: 2147839 [TBL] [Abstract][Full Text] [Related]
11. Chronic therapy of severe heart failure with enoximone. Gilfrich HJ; Witzke-Gross J; Römer A J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S75-7. PubMed ID: 2480490 [TBL] [Abstract][Full Text] [Related]
12. [Tolerance of enoximone in patients with heart failure]. Gilfrich HJ; Dieterich HA Z Kardiol; 1991; 80 Suppl 4():93-7. PubMed ID: 1833904 [TBL] [Abstract][Full Text] [Related]
13. Enoximone. A review of its pharmacological properties and therapeutic potential. Vernon MW; Heel RC; Brogden RN Drugs; 1991 Dec; 42(6):997-1017. PubMed ID: 1724645 [TBL] [Abstract][Full Text] [Related]
14. [New positive inotropic drugs in acute and chronic heart failure]. Follath F Schweiz Rundsch Med Prax; 1992 May; 81(21):704-7. PubMed ID: 1351309 [TBL] [Abstract][Full Text] [Related]
17. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method. Installe E; De Coster P; Gonzalez M; Brichant C; Lessire H; Cauwe F Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466 [TBL] [Abstract][Full Text] [Related]